IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0290480.html
   My bibliography  Save this article

Protocol for a multicentre randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss: The STARFISH trial

Author

Listed:
  • Matthew E Smith
  • Rachel Knappett
  • Deborah Vickers
  • David White
  • Chris J Schramm
  • Samir Mehta
  • Yongzhong Sun
  • Ben Watkins
  • Marie Chadburn
  • Hugh Jarrett
  • Karen James
  • Elizabeth Brettell
  • Tracy E Roberts
  • Manohar L Bance
  • INTEGRATE (the UK ENT Trainee Research Network)
  • James R Tysome

Abstract

Idiopathic sudden sensorineural hearing loss (ISSNHL) is the rapid onset of reduced hearing due to loss of function of the inner ear or hearing nerve of unknown aetiology. Evidence supports improved hearing recovery with early steroid treatment, via oral, intravenous, intratympanic or a combination of routes. The STARFISH trial aims to identify the most clinically and cost-effective route of administration of steroids as first-line treatment for ISSNHL. STARFISH is a pragmatic, multicentre, assessor-blinded, three-arm intervention, superiority randomised controlled trial (1:1:1) with an internal pilot (ISRCTN10535105, IRAS 1004878). 525 participants with ISSNHL will be recruited from approximately 75 UK Ear, Nose and Throat units. STARFISH will recruit adults with sensorineural hearing loss averaging 30dBHL or greater across three contiguous frequencies (confirmed via pure tone audiogram), with onset over a ≤3-day period, within four weeks of randomisation. Participants will be randomised to 1) oral prednisolone 1mg/Kg/day up to 60mg/day for 7 days; 2) intratympanic dexamethasone: three intratympanic injections 3.3mg/ml or 3.8mg/ml spaced 7±2 days apart; or 3) combined oral and intratympanic steroids. The primary outcome will be absolute improvement in pure tone audiogram average at 12-weeks following randomisation (0.5, 1.0, 2.0 and 4.0kHz). Secondary outcomes at 6 and 12 weeks will include: Speech, Spatial and Qualities of hearing scale, high frequency pure tone average thresholds (4.0, 6.0 and 8.0kHz), Arthur Boothroyd speech test, Vestibular Rehabilitation Benefit Questionnaire, Tinnitus Functional Index, adverse events and optional weekly online speech and pure tone hearing tests. A health economic assessment will be performed, and presented in terms of incremental cost effectiveness ratios, and cost per quality-adjusted life-year. Primary analyses will be by intention-to-treat. Oral prednisolone will be the reference. For the primary outcome, the difference between group means and 97.5% confidence intervals at each time-point will be estimated via a repeated measures mixed-effects linear regression model.

Suggested Citation

  • Matthew E Smith & Rachel Knappett & Deborah Vickers & David White & Chris J Schramm & Samir Mehta & Yongzhong Sun & Ben Watkins & Marie Chadburn & Hugh Jarrett & Karen James & Elizabeth Brettell & Tra, 2024. "Protocol for a multicentre randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss: The STARFISH trial," PLOS ONE, Public Library of Science, vol. 19(2), pages 1-19, February.
    • Handle: RePEc:plo:pone00:0290480
    DOI: 10.1371/journal.pone.0290480
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0290480
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290480&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0290480?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Gray, Alastair M. & Clarke, Philip M. & Wolstenholme, Jane L. & Wordsworth, Sarah, 2010. "Applied Methods of Cost-effectiveness Analysis in Healthcare," OUP Catalogue, Oxford University Press, number 9780199227280, Decembrie.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Julie A. Campbell & Glen J. Henson & Valery Fuh Ngwa & Hasnat Ahmad & Bruce V. Taylor & Ingrid Mei & Andrew J. Palmer, 2025. "Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modif," PharmacoEconomics, Springer, vol. 43(2), pages 223-239, February.
    2. David Lairson & Rohan Parikh & Janice Cormier & Wenyaw Chan & Xianglin Du, 2014. "Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer," PharmacoEconomics, Springer, vol. 32(10), pages 1005-1013, October.
    3. Michael Lebenbaum & Joyce Cheng & Claire Oliveira & Paul Kurdyak & Juveria Zaheer & Rebecca Hancock-Howard & Peter C. Coyte, 2020. "Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 189-201, April.
    4. Emma McManus, 2024. "Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model," PharmacoEconomics - Open, Springer, vol. 8(4), pages 569-583, July.
    5. Eric Kaun Santos Silva & June Alisson Westarb Cruz & Maria Alexandra Viegas Cortez Cunha & Thyago Proença Moraes & Sandro Marques & Eduardo Damião Silva, 2021. "Cost-effectiveness in health: consolidated research and contemporary challenges," Palgrave Communications, Palgrave Macmillan, vol. 8(1), pages 1-10, December.
    6. Edward C. F. Wilson & George Stanley & Zulfiquar Mirza, 2016. "The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke’s Encephalopathy Presenting at the Emerge," Applied Health Economics and Health Policy, Springer, vol. 14(2), pages 205-215, April.
    7. Lauren J. Christie & Nicola Fearn & Annie McCluskey & Meryl Lovarini & Reem Rendell & Alison Pearce, 2022. "Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project," PharmacoEconomics - Open, Springer, vol. 6(3), pages 437-450, May.
    8. Zanfina Ademi & Kumar Pasupathi & Danny Liew, 2017. "Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 363-374, June.
    9. Benjamin Ruban-Fell & George Attilakos & Tao Haskins-Coulter & Christopher Hyde & Jeanette Kusel & Anne Mackie & Oliver Rivero-Arias & Basky Thilaganathan & Nigel Thomson & Cristina Visintin & John Ma, 2022. "The impact of ultrasound-based antenatal screening strategies to detect vasa praevia in the United Kingdom: An exploratory study using decision analytic modelling methods," PLOS ONE, Public Library of Science, vol. 17(12), pages 1-18, December.
    10. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
    11. J. Jayasekera & E. Onukwugha & K. Bikov & C. Mullins & B. Seal & A. Hussain, 2014. "The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer," PharmacoEconomics, Springer, vol. 32(2), pages 173-191, February.
    12. Ernst, Richard, 2017. "Theories of Health Care Cost-Effectiveness Analysis," SocArXiv gjbcp, Center for Open Science.
    13. Afschin Gandjour & Amiram Gafni, 2013. "Internal validation of models with several interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 901-909, December.
    14. repec:osf:socarx:gjbcp_v1 is not listed on IDEAS
    15. Giuseppe Turchetti & S. Bellelli & M. Amato & S. Bianchi & P. Conti & A. Cupisti & V. Panichi & A. Rosati & F. Pizzarelli, 2017. "The social cost of chronic kidney disease in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 847-858, September.
    16. Stuart J. Wright & Ewan Gray & Gabriel Rogers & Anna Donten & Katherine Payne, 2024. "A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 527-542, July.
    17. Linda Ryen & Stefan Lundqvist & Åsa Cider & Mats Börjesson & Maria E. H. Larsson & Lars Hagberg, 2023. "Cost-Effectiveness of Prolonged Physical Activity on Prescription in Previously Non-Complying Patients: Impact of Physical Activity Mediators," IJERPH, MDPI, vol. 20(5), pages 1-14, February.
    18. Beata Wieczorek-Wójcik & Aleksandra Gaworska-Krzemińska & Aleksander Owczarek & Michał Wójcik & Monika Orzechowska & Dorota Kilańska, 2022. "The Influence of Nurse Education Level on Hospital Readmissions—A Cost-Effectiveness Analysis," IJERPH, MDPI, vol. 19(7), pages 1-15, March.
    19. Ilias Goranitis & Pelham Barton & Lee J Middleton & Jonathan J Deeks & Jane P Daniels & Pallavi Latthe & Arri Coomarasamy & Suneetha Rachaneni & Shanteela McCooty & Tina S Verghese & Tracy E Roberts, 2016. "Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-18, August.
    20. Nyi Nyi Zayar & Rassamee Chotipanvithayakul & Kyaw Ko Ko Htet & Virasakdi Chongsuvivatwong, 2022. "Programmatic Cost-Effectiveness of a Second-Time Visit to Detect New Tuberculosis and Diabetes Mellitus in TB Contact Tracing in Myanmar," IJERPH, MDPI, vol. 19(23), pages 1-12, December.
    21. Luke E Barry & Grainne E Crealey & Paul Cockwell & Stephen J Elliman & Matthew D Griffin & Alexander P Maxwell & Timothy O’Brien & Norberto Perico & Ciaran O’Neill, 2022. "Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 17(11), pages 1-12, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0290480. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.